Jaguar动物健康 JAGX 深 沪
等待开盘 05-22 09:30:00 美东时间
3.47
-0.200
-5.45%
华盛通- 最 高3.99
- 今 开3.10
- 成交量 35.74万股
- 最 低 3.10
- 昨 收 3.67
- 总市值 129.08万
- 52周最高 152.60
- 市盈率 静 --
- 换手率 96.07%
- 52周最低 2.53
- 委 比 -92.90%
- 总股本 37.20万
- 历史最高 87566062500.00
- 量 比 2.20
- 振 幅 24.25%
- 历史最低 3.10
- 每 手 1
- 风险率 38.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jaguar Health Q1 EPS $(13.60) Misses $(4.26) Estimate, Sales $20.272M Beat $4.211M Estimate
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(13.60) per share which missed the analyst consensus estimate of $(4.26) by 219.25 percent. This is a 97.67 percent increase over losses of $(584.45) per share
05-21 05:02
Jaguar Health's Napo Pharmaceuticals Announces That First Patient From Cohort Of Pediatric MVID Patients Has Entered The Active Treatment Only Single-Blind Extension To Study Safety And Efficacy
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) announced that the first patient from the cohort of pediatric MVID patients in the pivotal MVID randomized double-blind
05-19 21:11
Jaguar Health Stock Surges On FDA Breakthrough Discussions For Rare Disease Therapy
Jaguar Health Inc. shares are climbing Wednesday after preliminary FDA talks on Breakthrough Therapy Designation for oral liquid crofelemer.
05-06 21:26
Jaguar Health Boosts Public Float to Regain Nasdaq Compliance
Jaguar Animal Health ( ($JAGX) ) has shared an update. On May 1, 2026, Jaguar H...
05-05 06:55
Jaguar Health Announces Acceptance Of Two Late Breaking Abstracts To Treat Pediatric Intestinal Failure From Microvillus Inclusion Disease And Short Bowel Syndrome
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of two late breaking abstracts for the treatment of pediatric IF from MVID and SBS at the 58th Annual
04-24 20:32
Jaguar Health hosts investor webcast on Q4 2025 financials and company updates
Jaguar Health hosts investor webcast on Q4 2025 financials and company updates Jaguar Health schedules investor webcast on Q4 2025 financial results for April 10, 2026 at 8:30 a.m. Eastern. Webcast access: https://viavid.webcasts.com/starthere.jsp?ei=1754198&tp_key=0596f2aba1 . Replay link: https://
04-10 08:16
Jaguar Health reports Q4 results
Jaguar Health press release (JAGX): Q4 Revenue of $3.2M (-8.6% Y/Y). Net loss attributable to common shareholders increased by approximately $15.1 million, from $38.5 million in the year ended Decembe...
04-08 12:41
Jaguar Health FY25 net loss widens 37.6% to $54 million
Jaguar Health FY25 net loss widens 37.6% to $54 million Jaguar Health fiscal 2025 net loss widened 37.6% to $54 million. Revenue edged down 1.5% to $11.5 million. Operating loss expanded 48.9% to $45.9 million. Cash totaled $968,000 at Dec. 31, 2025, while stockholders’ deficit was $18.7 million. Ja
04-07 18:11
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
Jaguar Health's Napo Pharma Receives $3M Payment From Future Pak Following Termination By Jaguar Of Buy-Back Provision Of U.S. Licensing Agreement; Future Pak To Continue To Commercialize Mytesi Beyond Five Years
As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two
03-03 22:05
